GCTS

GRAND CANYON UNIVERSITY TO OPEN A 17,000-SQUARE-FOOT SEMINARY IN FALL 2023

Retrieved on: 
Monday, February 27, 2023

PHOENIX, Feb. 27, 2023 /PRNewswire/ -- Grand Canyon University will open a physical location for its Grand Canyon Theological Seminary, providing those students an opportunity to live on campus and incentives to receive more than half-off tuition as well as half-off housing. The campus-based Seminary will initially offer the Master of Divinity program, while also serving as an area where local pastors can connect with students and faculty, network, attend events and complete sermon preparation.

Key Points: 
  • PHOENIX, Feb. 27, 2023 /PRNewswire/ -- Grand Canyon University will open a physical location for its Grand Canyon Theological Seminary, providing those students an opportunity to live on campus and incentives to receive more than half-off tuition as well as half-off housing.
  • Seminary students will now have the option to take their classes in-person, during the day or early evening to fit their schedule.
  • The new space, located at 27th Avenue and Camelback Road, will feature large classrooms, meeting spaces and a 4,000-square-foot, extensive theological library.
  • "We believe that the seminary will become something like a relational incubator where pastors, students and faculty can connect, dialogue and encourage one another.

Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting

Retrieved on: 
Thursday, May 5, 2022

PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that an abstract on the results of the monotherapy portion of its ongoing Phase 2 trial of lead candidate onapristone extended release (ONA-XR) in granulosa cell tumors of the ovary was accepted for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022, at the McCormick Place Convention Center in Chicago, IL.

Key Points: 
  • We are thrilled that ASCO has recognized the potential of our novel clinical program for ONA-XR, a potent, specific progesterone receptor (PR) antagonist, in the treatment of granulosa cell tumors (GCTs) of the ovary, said Martin Lehr, CEO of Context Therapeutics.
  • GCTs are a rare form of ovarian cancer that is highly enriched for the target of ONA-XR.
  • We look forward to sharing the stage I monotherapy data at the conference and continuing enrollment of the stage II portion evaluating the combination of ONA-XR plus the antiestrogen anastrozole.
  • Context Therapeutics Inc. (Nasdaq: CNTX), is a womens oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers.

Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

Retrieved on: 
Monday, November 15, 2021

LineaRx has recorded an uptick in CRO orders for LinearDNA in recent quarters.

Key Points: 
  • LineaRx has recorded an uptick in CRO orders for LinearDNA in recent quarters.
  • CRO customers are also evaluating LinearDNA for use in mRNA template manufacture, recombinant adeno-associated virus manufacture, and in vivo expression vectors.
  • Unlike plasmid-derived DNA, LinearDNA is free of adventitious DNA sequences and can be chemically modified to optimize the DNA for specific applications.
  • Applied DNA has also established a COVID-19 diagnostic and testing offering that is grounded in the Companys deep expertise in DNA.

QIMA Approved as a Gulf Mark Notified Body Gulf Standardization Organization

Retrieved on: 
Wednesday, October 20, 2021

All products governed by a Gulf Technical Regulation are required to display a GSO Conformity Tracking Symbol (GCTS) which consists of the G-Mark and a QR Code.

Key Points: 
  • All products governed by a Gulf Technical Regulation are required to display a GSO Conformity Tracking Symbol (GCTS) which consists of the G-Mark and a QR Code.
  • As an approved Notified Body, QIMA is able to carry out a conformity assessment to ensure products meet the GSO's technical regulations and are fit for use in the Gulf countries' common market.
  • "The Gulf region is a thriving market and we are delighted to be approved as Notified Body by the GSO to ensure the safety of children's toys and LVE being sold there."
  • For all our clients in 120 countries who use the QIMA platform and benefit from 24/7 support in over 20 languages, QIMA is Your Eyes in the Supply Chain.

GCT Investment Advances Capability at Vanterm Terminal with Two Modern Ship-to-Shore Cranes in the Burrard Inlet

Retrieved on: 
Friday, November 27, 2020

Vancouver, B.C., Nov. 27, 2020 (GLOBE NEWSWIRE) -- On November 27, 2020, GCT Global Container Terminals Inc. accepted the delivery of two modern 14,000 TEU capable ship-to-shore cranes at GCT Vanterm in Burrard Inlet in the Vancouver Harbour.

Key Points: 
  • Vancouver, B.C., Nov. 27, 2020 (GLOBE NEWSWIRE) -- On November 27, 2020, GCT Global Container Terminals Inc. accepted the delivery of two modern 14,000 TEU capable ship-to-shore cranes at GCT Vanterm in Burrard Inlet in the Vancouver Harbour.
  • After travelling roughly 9,200 km or 5,000 nautical miles from Shanghai, the two cranes passed safely under the Lions Gate Bridge earlier this week and arrived at GCT Vanterm.
  • This advancement is part of GCTs previously announced $160-million-dollar private sector investment to modernize and densify operations at GCT Vanterm.
  • On the West Coast, GCT Canada operates two gateway terminals: GCT Vanterm and GCT Deltaport in Vancouver and Delta, BC.

Global Cancer Technology launches Regulation CF equity crowdfunding campaign

Retrieved on: 
Tuesday, October 29, 2019

Global Cancer Technology (GCT) announced today that it has launched an equity crowdfunding campaign under Regulation CF guidelines.

Key Points: 
  • Global Cancer Technology (GCT) announced today that it has launched an equity crowdfunding campaign under Regulation CF guidelines.
  • A successful Reg CF fundraise will fast-forward our efforts to translate GCTs innovative and patented technology and realize the potential to significantly improve anticancer treatment outcomes, said John Clark, CEO.
  • The SNC platform is exclusively licensed to the company from the University of California San Diego (UCSD).
  • San Diego-based Global Cancer Technology is an emerging medical technology company with a robust pipeline focused on fighting cancer.